Recent clinical and preclinical studies have shown that hyperkinetic disorders such as Huntington's disease, dystonia and l-DOPA-induced dyskinesia in Parkinson's disease are all characterized by loss of the ability to reverse synaptic plasticity and an associated increase in the excitability of excitatory neuronal inputs to a range of cortical and subcortical brain areas. Moreover, these changes have been detected in humans with hyperkinetic disorders either via direct recordings from implanted deep brain electrodes or noninvasively using transcranial magnetic stimulation. Here we discuss the mechanisms underlying the loss of bidirectional plasticity and the possibility that future interventions could be devised to reverse these changes in patients with hyperkinetic movement disorders.
p e r s p e c t i v e
Recent clinical and preclinical studies have shown that hyperkinetic disorders such as Huntington's disease, dystonia and l-DOPA-induced dyskinesia in Parkinson's disease are all characterized by loss of the ability to reverse synaptic plasticity and an associated increase in the excitability of excitatory neuronal inputs to a range of cortical and subcortical brain areas. Moreover, these changes have been detected in humans with hyperkinetic disorders either via direct recordings from implanted deep brain electrodes or noninvasively using transcranial magnetic stimulation. Here we discuss the mechanisms underlying the loss of bidirectional plasticity and the possibility that future interventions could be devised to reverse these changes in patients with hyperkinetic movement disorders.
The ability to adjust movements to fit task requirements employs plastic mechanisms operating at the level of cortex and striatum 1 . These mechanisms regulate the excitability of output structures and limit excessive neuronal activity without compromising the stability and integrity of the underlying circuits that drive behavior. This ability allows neurons to sense their functional state and to adjust their properties to maintain stable function.
Physiological adaptations related to motor learning require neural networks to detect correlations between environmental events and to store this information as changes in synaptic strength. Classical examples of brain-activity-dependent adaptations are long-term potentiation (LTP) and long-term depression (LTD) 2 . However, excessive expression of these forms of plasticity can be detrimental for behavior and motor activity. In this Perspective we propose that the loss of synaptic downscaling alters LTP regulation in the basal ganglia, as well as in the cortex, leading to hyperkinetic movement disorders.
Huntington's disease (HD), dystonia and l-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD) can all be classified as hyperkinetic disorders although they differ in the nature (choreic, dystonic, etc.) of the predominant motor manifestation. Recent advances in genetic, molecular and imaging studies have allowed a better understanding of the similarities and differences between them 3 . It has been suggested that LID, dystonia and HD share several molecular and synaptic abnormalities, which may seem surprising since distinct neuronal subtypes are affected by the different pathologies. Yet, as we show below, all can lead to changes in control of synaptic plasticity.
HD is a progressive neurodegenerative disorder, causing movement, mood and cognitive alterations, that profoundly impairs processing of corticostriatal information 4 . While late pathology in HD is accompanied by severe neuronal loss, early motor manifestations are associated with subtle functional alterations in the excitatory synaptic activity and in the formation of aberrant cortical and subcortical plasticity 5 . In the early stage of HD, neuronal death is rare. Similarly, neurodegeneration is not typically encountered in primary dystonias throughout evolution; instead they are associated with an imbalance of transmitters and other biochemical abnormalities 6, 7 . From the pathophysiological point of view, the pathogenesis of LID in PD is more complex. Severe loss of nigral dopaminergic neurons, leading to a dramatic striatal dopamine depletion, is an essential precondition for the expression of LID 8, 9 . However, hyperkinesias only occur if associated with subtle alterations of the dendritic spines of cortical and striatal neurons 10, 11 .
Cortical and striatal pathological synaptic potentiation of excitatory transmission in experimental models of HD HD is induced by a polyglutamine expansion in the huntingtin (Htt) protein 5 . Genetic mouse models of HD have contributed to a better knowledge of the cellular and molecular mechanisms underlying the pathogenesis of HD. The neurodegenerative process starts earlier in the striatum than in other brain areas, and abnormal activity of glutamatergic corticostriatal synapses contributes to an imbalance in survival-versus death-signaling pathways in the striatum 4, 12 . Striatal projection neurons (SPNs) of the indirect pathway seem more vulnerable than those of the direct pathway, and their dysfunction contributes to motor manifestations during early stages of the disease 13 . Since the striatum is the primary site of neurodegeneration, it has been hypothesized that downscaling of the plasticity of striatal glutamatergic synapses on striatal neurons is impaired and that this leads to early cognitive and motor symptoms. In support of this hypothesis, alterations in the induction and reversal of synaptic plasticity have been demonstrated in a genetic (R6/2 mice) model of the disease. SPNs in this model have been shown to express normal LTP, but to be unable to depotentiate their synapses after a lowfrequency stimulation (LFS) protocol (Fig. 1) 14 . The inability of SPNs to reverse synaptic strength to pre-LTP levels disrupts regulatory processes that destabilize neuronal circuits during information storage and could contribute to the impaired behavioral flexibility described in early-stage HD 14 .
It has been proposed that reduced brain-derived neurotrophic factor (BDNF) transcription, transport and signaling contribute to striatal neuronal dysfunction and degeneration in HD 5 . p e r s p e c t i v e However, this view has recently been challenged, since in mouse models of early symptomatic HD, BDNF delivery to the striatum and its activation of tyrosine-related kinase B (TrkB) receptors were found to be normal, while TrkB receptor activation resulted in an aberrant postsynaptic control of potentiation induction at corticostriatal synapses 15 . It seems likely that the expression of mutant Htt causes a change in striatal excitatory synaptic activity, triggered by a decrease of glutamate uptake and by increased signaling at NMDA receptors 16 .
Striatal dopamine signaling is also altered in HD and progresses through the course of the disease 17 . Alterations of A2A adenosine receptors (A2AR) mirror changes in the dopamine system since both dopamine and A2AR converge on the regulation of the cAMP-protein kinase A (PKA)-dopamine-and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) pathway, which is activated by G-proteinassociated receptors. This pathway, in turn, regulates the efficacy of glutamatergic transmission and striatal plasticity (Fig. 2) 18, 19 . Upregulation of PKA activity and increased function of A2AR are also seen in HD [19] [20] [21] [22] . Accordingly, genetic inactivation or pharmacological manipulation of A2AR prevent or reverse working memory deficits in early HD, respectively 23 .
On the basis of clinical and experimental findings, it has been hypothesized that some of the behavioral alterations in HD, including reduced behavioral flexibility, may be caused by altered dopamine modulatory function 24 . Interestingly, aberrant synaptic plasticity and dopaminergic dysfunction have been shown not only in the striatum but also in the cortex of a mouse model of HD 25 .
Altered spine and synaptic plasticity could underlie the motor features as well as cognitive features of HD. Recently, a novel imaging technique was used to study spine alteration kinetics associated with plastic changes in the R6/2 genetic model of HD 26 . In R6/2 mice the probability that newly formed spines will stabilize and transform into persistent spines is greatly reduced compared to that in controls, and in R6/2 mice, aggregates of mutant Htt are localized to dendritic spines. The evidence that alterations in dendritic spine dynamics, survival and density in R6/2 mice appear before the onset of motor symptoms indicates that decreased stability of the cortical synaptic circuitry underlies the early symptoms in HD.
Experimental models of HD suggest that striatal grafts might rescue motor deficits and learning of complex motor skills in experimental models of HD. Embryonic striatal grafts create functional connections with the host striatal circuitry and restore synaptic transmission, facilitating the recovery of bidirectional synaptic plasticity 27 .
Aberrant synaptic plasticity in experimental models of dystonia Dystonia is characterized by sustained muscle contractions causing twisting repetitive movements and abnormal postures. Dystonia can be classified by age at onset, by distribution (focal, segmental, generalized or hemidystonia) or by etiology (idiopathic or secondary) 28 . Most idiopathic dystonias are believed to have genetic origins 3 . The discovery of genes implicated in dystonia as well as the experimental use of new genetic models has provided information about the disease mechanisms 29 . Unfortunately, most of these rodent models do not exhibit overt dystonia, although they show subtle motor abnormalities with peculiar neurochemical and neurophysiological alterations. Among the various synaptic and electrophysiological alterations described in these models, a major common characteristic seems to be abnormal corticostriatal synaptic plasticity. Early-onset DYT1 dystonia, the most common and severe form of inherited dystonia, is caused by a 3-bp deletion affecting a glutamic acid residue in the C-terminal coding region of the protein torsinA 30 . In transgenic mice overexpressing mutant torsinA, no corticostriatal LTD can be elicited, whereas LTP is greater than in control animals. Moreover, while LFS reverts potentiated synapses to resting levels (depotentiation) in control mice, this phenomenon is absent in mutant mice (Fig. 1) 31 . Notably, these abnormalities in synaptic plasticity are reproducible across species and distinct mouse lines, as they are found both in transgenic rats overexpressing mutant torsinA 32 and in knock-in mice heterozygous for ∆-torsinA (Tor1a +/∆gag ) 33 . Collectively, these findings confirm the existence of a specific endophenotype linked to DYT1 mutation and indicate that the loss of downscaling is a distinctive feature in multiple models of DYT1 dystonia. npg p e r s p e c t i v e
A major contributor to the aberrant control of synaptic plasticity in the DYT1 model appears to be a breakdown of the usual reciprocal relationship between striatal dopamine and acetylcholine 34, 35 , due to a change in regulation of cholinergic activity by the D2 dopamine receptor. Data collected from different rodent models of DYT1 dystonia show that the D2 receptor agonist quinpirole produces a paradoxical excitation of cholinergic interneurons, rather than inhibition 36,37 . The consequent imbalance in neurotransmitter content impairs bidirectional corticostriatal synaptic plasticity, which can then be restored by anticholinergic drugs. This is consistent with the clinical use of anticholinergic agents in dystonia and offers a rationale for the development of improved antimuscarinic therapies. Moreover, a relevant link has been demonstrated between torsinA mutations and D2 receptor: A2AR antagonism counteracts the D2 receptor deficit observed in mutant mice, suggesting that modulation of PKA is a critical pathophysiological factor (Fig. 2) 38 .
Anticholinergic drugs reverse the deficit in motor control and restore striatal LTD in Dyt1 ∆GAG heterozygous knock-in (KI) mice carrying one Dyt1 allele with the trinucleotide deletion 39 . Another study, using a model showing conditional deletion of torsinA in embryonic progenitors of forebrain cholinergic and GABAergic neurons, observed that the onset of dystonic movements correlates with degeneration of striatal cholinergic interneurons, while remaining interneurons show morphological and electrophysiological alterations. More importantly, abnormal movements were significantly reduced with an antimuscarinic drug 40 . Taken together, these findings support the hypothesis that impaired balance among glutamatergic inputs, cholinergic interneurons, responses to dopaminergic signal and SPN activity are involved in the motor abnormalities in DYT1 dystonia 41 .
Synaptic dysfunctions in experimental models of l-DOPAinduced dyskinesia in PD l-DOPA initially revolutionized the symptomatic treatment of PD 42 . Unfortunately, long-term treatment becomes complicated in most patients with increasingly frequent motor fluctuations and hyperkinetic involuntary movements 8 . It has been hypothesized that the development of LID is linked to impaired synaptic plasticity at corticostriatal synapses and, in particular, to the loss of synaptic depotentiation 43 . Indeed, dopamine denervation in rats using the toxin 6-hydroxy-dopamine (6-OHDA) causes loss of corticostriatal LTP that can be restored by chronic l-DOPA treatment (Fig. 1) 43 . Remarkably, only 6-OHDA-lesioned animals that develop dyskinetic movements show an absence of depotentiation; this form of plasticity is preserved in animals that do not develop LID (Fig. 1) 43 . This suggests that loss of synaptic depotentiation might destabilize neuronal circuits in the basal ganglia, resulting in dyskinesias.
Abnormalities of synaptic plasticity in dyskinetic animals are related to changes in the D1-PKA-DARPP-32 signaling pathway that inhibit the activity of protein phosphatase (PP) 1 (Fig. 2) , a molecule involved in depotentiation at corticostriatal synapses. Activation of D1 receptors causes the PKA-induced phosphorylation on Thr34 of DARPP-32. This event in turn inhibits PP-1. Notably, only the 6-OHDA-lesioned animals that develop LID show increased phosphorylation of Thr34-DARPP-32. Accordingly, pretreatment with PP-1 and PP-2A inhibitors, D1-like-receptor agonists and adenylyl cyclase activators prevents the induction of physiological striatal depotentiation 43 .
The Ras-extracellular-signal-regulated kinase (Ras-ERK) pathway controls synaptic activity in SPNs and represents a critical signaling pathway downstream of the D1 receptor 44 . Notably, a recent study has shown that the Ras-ERK pathway regulates both activitydependent striatal LTP and synaptic depotentiation. Mice bearing a mutation of the gene encoding Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a guanine nucleotide exchange factor that activates Ras proteins, show absence of LTP selectively in striatonigral SPNs. When mutants are subjected to unilateral injection of 6-OHDA and chronic l-DOPA treatment, characterization of LTP in dyskinetic mice shows an involvement of ERK that is Ras-GRF1-and pathway-independent 44 .
A possible way to reduce LID involves targeting striatal phosphodiesterases, which regulate intracellular levels of cGMP 45 . The phosphodiesterase inhibitors zaprinast and UK-343664 rescue the loss of LTD at corticostriatal synapses via a mechanism requiring the modulation of intracellular cGMP levels. Intrastriatal injection of these drugs is also associated with reduced LID, thus supporting the idea that targeting phosphodiesterases can ameliorate LID by facilitating the re-emergence of striatal LTD 45 . Moreover, a recent study has shown that a complex serotonergic regulation of striatal bidirectional synaptic plasticity underlies the antidyskinetic effect of serotonergic agonists 46 .
Another electrophysiological approach used to study the molecular mechanisms of dyskinesia is the spike-timing-dependent plasticity (STDP) at corticostriatal synapses. In particular, synaptic alterations occurring in direct or indirect output pathways of 6-OHDA-lesioned and dyskinetic bacterial artificial chromosome (BAC) transgenic mice with eGFP targeting the direct or indirect output pathways have been investigated 47 . In control mice, bidirectional synaptic plasticity (LTP, LTD and depotentiation) can be observed in both striatal output pathways. In dopamine-denervated mice, direct and indirect pathway 
exhibit only unidirectional plasticity, regardless of the stimulation paradigm. l-DOPA treatment re-establishes physiological bidirectional plasticity in both direct and indirect pathways. While the antidyskinetic effect of l-DOPA is associated with the rescue of bidirectional plasticity in both pathways, in animals responding with LID, l-DOPA treatment achieves recovery of LTD in the indirect pathway and of LTP in the direct pathway. Thus, this study supports the concept that bidirectional plasticity of both striatonigral and striatopallidal outputs is a necessary condition to ensure correct motor control, while dyskinetic movements are caused by an abnormal segregation of plasticity between the two pathways.
Another recent study suggests that STDP in PD and in LID is cell-type specific. In fact, the intrinsic excitability and corticostriatal synaptic connectivity of SPNs in the indirect pathway are lower in PD model animals than in healthy controls. Conversely, these properties of SPNs in the direct pathway are enhanced in tissues from PD models and suppressed in LID models 48 .
Transcranial magnetic stimulation and dysfunctional plasticity in the cortex in hyperkinetic disorders Transcranial magnetic stimulation (TMS) is a noninvasive method of stimulating the brain in conscious humans. Because it is not possible to stimulate deep brain structures such as basal ganglia reliably, the motor cortex has been the target in most studies of hyperkinetic movement disorders. TMS has the advantage that the response is easily quantified by measuring the size of the movement it evokes in contralateral muscles. Motor cortex shows early degenerative changes (for example, in HD 49 ), receives dopaminergic innervation that influences synaptic plasticity 50 , and is a primary output target of basal-ganglia-thalamo-cortical circuits. Thus, it might be expected to reflect some of the changes described in striatal connections.
A number of common TMS methods have been used in hyperkinetic movement disorders to probe several aspects: (i) the excitability of cortico-spinal connections (motor thresholds), (ii) GABA A cortical inhibition (short interval intracortical inhibition, or SICI), (iii) GABA B inhibition (silent period), (iv) a cholinergic-sensitive form of inhibition (short-latency afferent inhibition) and (v) the initial stages of synaptic plasticity leading to LTP and LTD. These methods include repetitive TMS (rTMS), theta burst stimulation (TBS) and paired associative stimulation (PAS), a form of STDP 51 . Responses to these methods vary considerably between individuals, so that none is diagnostic. However, group differences are reliable given sufficiently large sample sizes.
Huntington's disease. Initial work on HD focused on measures of excitability and inhibition in clinically manifesting individuals. They appeared to suggest that the excitability of GABA A systems (SICI method) were reduced 52 whereas GABA B (silent period) seemed elevated 53,54 . However, later studies sometimes failed to replicate these findings 55 , suggesting that the effects are small, if present. One report found reduced cholinergic-sensitive inhibition (short-latency afferent inhibition), which was even present in preclinical cases, but this has not been replicated 55 .
The effects of HD on plasticity are clearer. Three studies using different forms of plasticity-probing methods (rTMS, TBS and PAS) all reported smaller responses than normal [56] [57] [58] , which would be consistent with the idea that plasticity at cortical synapses is reduced. Notably, between them these methods probed both facilitatory (LTP-like) and inhibitory (LTD-like) effects and found that these effects occurred even in non-symptomatic carriers, suggesting early cortical involvement in HD before the appearance of clinical signs 58 .
Dystonia. As in HD, initial studies concentrated on measures of cortical excitability and GABA function. The majority of studies reported reduced GABA A excitability (SICI) in many types of focal dystonia [59] [60] [61] . As usual, the effects are probably smaller than in the initial reports 62, 63 . Similarly GABA B (silent period) has also been found to be reduced in most reports 59, 64, 65 , but not always 66 . Other forms of inhibition have also been reported as reduced in people with dystonia, such as 'surround inhibition' (suppression of excitability in uninvolved hand muscles when people try to produce a focal contraction of just one muscle 67 ) and inhibition from premotor to motor cortex 68 . All these studies are compatible with the notion that disordered control of inhibitory systems in motor cortex might contribute to the excess muscle activity characteristic of dystonia. However, in people with focal dystonia these changes can often be observed in clinically unaffected parts of the body. Building on the work in experimental animals, a large number of studies have focused on cortical plasticity in dystonia. Initial work 69, 70 found a pronounced increase in the responsiveness to tests of both LTP-like and LTD-like npg p e r s p e c t i v e plasticity (PAS protocol). Although this has been replicated in several later studies [71] [72] [73] [74] , it is not a universal finding 75 , probably because of the inter-individual variation in the effect size. Notably it is easier to demonstrate increased plasticity in people with organic dystonia than in "psychogenic" cases, suggesting that plasticity is an important contributor to clinical manifestations 76 . Finally, within individuals, there is reduced control of plasticity in dystonia 77, 78 .
Parkinson's disease and LID. Most of the work examining differences between people with and without dyskinesia has focused on measures of cortical plasticity. The initial study by Morgante et al. 79 found a lack of LTP-like plasticity (PAS protocol) in people when off treatment and found that LTP-like plasticity was restored after administration of l-DOPA. Importantly, this effect was not seen in people who had LID, consistent with a lack of dopaminergic modulation of synaptic plasticity in these cases. More recently, Huang et al. 60 introduced a TMS method for probing depotentiation of LTP-like plasticity. Consistent with the animal models, humans with LID were unresponsive to the depotentiation protocol (Fig. 3) 80 , suggesting that depotentiation in the motor cortex of humans with LID is abnormal.
Deep brain stimulation and aberrant plasticity in the basal ganglia in hyperkinetic disorders Deep brain stimulation (DBS), using high-frequency electrical stimulation of deep brain structures, is an effective therapeutic option for treatment of a variety of neurological and psychiatric disorders 81 . DBS targeting the internal segment of the globus pallidus (GPi), subthalamic nucleus (STN) and thalamus is used to treat movement disorders such as PD, LID in PD, and dystonia (Fig. 4) . The first study that characterized synaptic plasticity in people with PD with DBS electrodes implanted in the STN measured field potentials (fEPs) in substantia nigra pars reticulata (SNr) that were evoked by stimulation through a nearby microelectrode 82 . High-frequency stimulation (HFS) in the SNr failed to induce a lasting change in test fEPs in people not on medication, whereas it potentiated fEP amplitudes after oral l-DOPA administration, indicating that medication that elevates dopamine restores LTP-like changes in the human basal ganglia. In a more recent study, the same group analyzed whether LFS in the GPi and SNr could depotentiate synapses that had already undergone HFS-induced potentiation 83 . GPi and SNr synapses in people with PD with less severe LID underwent greater depotentiation following LFS than in those with more severe LID (Fig. 4) . This demonstration of impaired depotentiation in basal ganglia output nuclei in people with PD with dyskinesia is an important validation of animal models of LID. Indeed, the ability of a synapse to reverse previous potentiation may be crucial to the normal function of the basal ganglia, avoiding storage of non-essential motor information.
DBS of the GPi is an excellent treatment for primary generalized or segmental dystonia. It is less effective for dystonia secondary to structural brain damage 84 . It has been hypothesized that DBS suppresses abnormally enhanced synchronized oscillatory activity in the motor cortex-basal ganglia network. Accordingly, pallidal DBS suppresses pathologically enhanced low-frequency activity in patients with dystonia 85 .
Electrophysiological features of dystonia in patients before and in the early treatment period following pallidal DBS have been assessed longitudinally 86 . Following DBS, short-latency intracortical inhibition increases toward normal levels with the same time course as the patients' clinical benefit 87 . In contrast, synaptic plasticity changes rapidly, following a different time course. Clinical benefits may be delayed because engrams of abnormal movement persist and take time to normalize, which would suggest that plasticity may be a driver of long-term therapeutic effects of DBS in dystonia.
DBS treatment of HD is in an exploratory phase and the optimal brain structure to be targeted has yet to be determined. The number of patients treated with DBS for HD is small; however, preliminary studies show benefits following internal and external GPi stimulation. The thalamus, STN and substantia nigra pars compacta could also be potential targets. Further clinical studies are necessary to validate the efficacy of neuromodulation and to determine the optimal target for HD 88 .
Abnormal excitability as a target for therapeutic interventions in hyperkinetic movement disorders In the last decade rTMS has been widely used as a possible treatment for both PD and hyperkinetic movement disorders. Although studies on the efficacy of rTMS in treating movement have produced variable results, mostly owing to the variety of different rTMS protocols, data suggest a possible therapeutic effect of rTMS. Relevant modulators of rTMS efficacy are site, frequency and number of pulses 89, 90 . Most studies have focused on the treatment of PD with LID and npg p e r s p e c t i v e on dystonia, while only a few reports have reported data on HD. In most of these therapeutic trials, the driving hypothesis has been the attempt to restore the physiological bidirectional plasticity that in hyperkinetic disorders might be lost at cortical and subcortical levels.
The most complete set of data is for rTMS treatment of PD, where there have been more than one hundred studies. The results of the most robust of these trials are summarized in the review by Lefaucheur et al. 91 . The consensus is that rTMS over primary motor cortex, premotor or supplementary motor areas may have some potential clinical benefit but that the effects so far reported are too small to be of use in clinical practice.
There has also been interest in using rTMS to reduce LID. Interestingly, rTMS at 1 Hz but not at 5 Hz over the supplementary motor area in a group of patients with advanced PD reduced dyskinesias induced by continuous apomorphine infusion (Fig. 3) 92 . This observation indicates that the most effective therapeutic protocol is similar to the one producing depotentiation in animal studies. The existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on LID in PD has been also demonstrated in a placebo-controlled, singleblind crossover study 93 .
Some studies have explored the possibility that LID can be reduced by targeting brain structures that are not included in the 'classical' basal ganglia circuits. Continuous theta burst stimulation of the cerebellum may have anti-dyskinetic effects, possibly via the modulation of cerebello-thalamocortical pathways 94 . A study combining resting state functional MRI with rTMS has shown that the inferior frontal cortex is implicated in LID and could be a potential therapeutic target 95 .
In dystonia, increased cortical excitability of the motor cortex and the brain stem 96 could be a target for rTMS modulation. Again, the consensus at the present time 91 from the small number of studies that have been completed is that any effects are small and at present are not of clinical relevance.
Case studies report improvement in choreiform movements with administration of low-frequency rTMS lasting for a brief period 97 . However, other case series using bilateral low-frequency rTMS in severe HD failed to replicate the findings 98 .
Conclusions
Both experimental and clinical findings suggest that in hyperkinetic disorders not only distinct but also common mechanisms interact at both cellular and network levels to influence synaptic scaling and synaptic plasticity. Under physiological conditions, the compartmentalization of synaptic plasticity to specific connections and neuronal populations facilitates appropriate information storage of motor-related signals. In hyperkinetic disorders, the specificity of cellular and network-related plasticity is lost, with the results that cortex and basal ganglia store redundant information. This loss of specificity in hyperkinetic disorders can occur at different levels and is linked to the genetic and/or molecular bases underlying the disease: (i) abnormalities of activity-dependent posttranslational modifications of synaptic proteins at the activated synapses, (ii) paradoxical local protein synthesis and degradation at synapses and (iii) disruption of the molecular mechanisms contributing to depotentiation.
Clinical electrophysiological studies using TMS and DBS (Figs. 3  and 4) have confirmed the role of maladaptive plasticity in hyperkinetic disorders. More importantly, these methods are now commonly used to target this pathological plasticity and ameliorate some of the symptoms associated with these disorders. At present, however, there is still a gap in the knowledge on the reciprocal links between plastic changes occurring in the basal ganglia and aberrant plasticity observed in the cortex. In fact, while most electrophysiological studies on animal models of hyperkinetic disorders have focused on basal ganglia circuits, clinical electrophysiological studies using TMS mostly target cortical circuits (motor cortex) 58, 99, 100 . Although this gap should be filled in future studies, loss of downscaling in both cortical and subcortical structures might represent a common synaptic mechanism occurring in distinct hyperkinetic disorders, as detected using neurophysiological approaches (Fig. 5) . npg p e r s p e c t i v e
